In brief
Diabetes is a structural shift in global pharma strategy, not just a clinical trend: rising prevalence in the Middle East, Africa, and Asia is turning former "secondary" markets into central battlegrounds for diabetes care. The core argument is that managing diabetes well demands more than a drug — it requires portfolio breadth, distribution reach, regulatory fluency across multiple jurisdictions, and resilient manufacturing partnerships, sustained over years rather than a single launch.
Table of contents
A condition on the rise
Diabetes now affects hundreds of millions of people worldwide, and the numbers keep climbing. Type 2 diabetes, once associated mainly with aging populations in wealthier countries, is increasingly diagnosed earlier in life and is rising sharply across the Middle East, Africa, and Asia — regions undergoing rapid urbanization, dietary shifts, and lifestyle change.
This shift matters for how the pharmaceutical industry plans ahead. Markets that were once considered secondary are now central to global diabetes care strategy, driving demand for insulin, oral antidiabetics, and newer drug classes, alongside diagnostic tools and long-term disease management support.
Why pharma's role is expanding
Managing diabetes well requires more than a single medicine. It typically involves ongoing monitoring, combination therapies, and treatment adjustments over years or decades.
That reality is reshaping what's expected of pharmaceutical companies operating in this space:
- Portfolio breadth. Patients need options across different stages and types of the disease — from first-line oral therapies to insulin analogues to the newer incretin-based treatments that have reshaped the treatment landscape in recent years.
- Access and affordability. In many high-growth markets, affordability and distribution reach matter as much as innovation. Getting essential and established therapies to pharmacies and hospitals — not just capital cities — is often the harder problem to solve.
- Regulatory navigation. Bringing a diabetes therapy to market in multiple countries means navigating different regulatory codes, registration processes, and health authority requirements, often in parallel.
- Local manufacturing and supply partnerships. Outsourced and regional manufacturing models, built through partnerships with certified production sites, are increasingly used to keep supply chains resilient and costs manageable.
A chronic condition, a long-term commitment
Diabetes is a chronic and, at present, largely lifelong condition. That has a direct implication for how pharmaceutical companies build their business models: this isn't a category built around a single product launch, but around sustained relationships with patients, healthcare providers, and health systems over time.
For companies expanding into fast-growing regions, this often means building local regulatory and commercial infrastructure early, rather than treating market entry as an afterthought. It also means treatment portfolios need to evolve — chronic and metabolic conditions like diabetes sit alongside other rising non-communicable diseases as a growing share of what regional health systems need to manage.
What's next
As demand grows in underserved and fast-growing markets, the companies best positioned to meet it will be those that combine registered, accessible products with real distribution reach — pharmacy networks, hospital partnerships, and regulatory relationships built for the long term, not just a single market entry.
Diabetes care is, ultimately, a marathon rather than a sprint — for patients and for the companies that supply their treatment. Meeting that challenge means thinking in years and decades, not quarters.
This article is intended for general informational purposes and does not constitute medical advice. Individuals managing diabetes should consult a qualified healthcare professional regarding diagnosis and treatment.